(Q33393514)

26 July 2017

title

Iniparib plus chemotherapy in metastatic triple-negative breast cancer (English)

1 reference

26 July 2017

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

21 November 2024

1 reference

1 reference

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

Poly(ADP-ribose) polymerase inhibitors

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21208101

21 November 2024

1

Joyce O'Shaughnessy

1 reference

26 July 2017

Cynthia Osborne

2

1 reference

26 July 2017

Mark Yoffe

4

1 reference

26 July 2017

Debra Patt

5

1 reference

26 July 2017

Christine Rocha

6

1 reference

26 July 2017

Ingrid Chou Koo

7

1 reference

26 July 2017

Charles Bradley

9

1 reference

26 July 2017

John E. Pippen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21208101

21 November 2024

Barry M. Sherman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21208101

21 November 2024

language of work or name

English

0 references

publication date

5 January 2011

1 reference

full work available at URL

26 July 2017

http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21208101

http://content.nejm.org/cgi/content/abstract/364/3/205

21 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21208101

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011418

21 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

The New England Journal of Medicine

21 November 2024

published in

1 reference

26 July 2017

volume

364

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

205-214

1 reference

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

26 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Pattern of metastatic spread in triple-negative breast cancer

21 November 2024

2

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

21 November 2024

3

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 November 2024

4

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 November 2024

5

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

21 November 2024

6

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 November 2024

7

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Negative Regulation of BRCA1 Gene Expression by HMGA1 Proteins Accounts for the Reduced BRCA1 Protein Levels in Sporadic Breast Carcinoma

21 November 2024

9

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

21 November 2024

10

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 November 2024

11

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

BRCA1 dysfunction in sporadic basal-like breast cancer

21 November 2024

12

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene

21 November 2024

13

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype

21 November 2024

14

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 November 2024

15

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer

21 November 2024

16

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

21 November 2024

17

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin

21 November 2024

19

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer

21 November 2024

20

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer

21 November 2024

21

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer

21 November 2024

22

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway

21 November 2024

23

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Stemming the tide of hepatitis B virus related hepatocellular carcinoma?

21 November 2024

24

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 November 2024

25

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 November 2024

26

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 November 2024

27

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 November 2024

28

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 November 2024

29

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1011418

21 November 2024

Identifiers

1 reference

26 July 2017

1 reference